Drug Profile


Alternative Names: CaPre; NKPL-66; Omega-3 phospholipid - Acasti Pharma

Latest Information Update: 26 Apr 2017

Price : $50

At a glance

  • Originator Acasti Pharma
  • Class Antihyperlipidaemics; Phospholipids
  • Mechanism of Action Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hypertriglyceridaemia

Most Recent Events

  • 24 Apr 2017 Acasti Pharma is granted additional patents for NKPL 66 in Australia and Taiwan
  • 30 Mar 2017 Acasti plans two phase III clinical trials for Hypertriglyceridaemia in USA
  • 12 Jan 2017 Acasti Pharma completes a pharmacokinetic trial in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top